Raltegravir, lopinavir, ritonavir — Competitive Intelligence Brief

Raltegravir, lopinavir, ritonavir (Raltegravir, lopinavir, ritonavir) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (integrase inhibitor + protease inhibitors). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (integrase inhibitor + protease inhibitors) HIV integrase, HIV protease Infectious Disease / Virology Small molecule

Target snapshot

Raltegravir, lopinavir, ritonavir (Raltegravir, lopinavir, ritonavir) — Allina Health System. This combination of three antiretroviral drugs inhibits HIV replication by blocking integrase (raltegravir) and protease (lopinavir/ritonavir) enzymes essential for viral reproduction.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Raltegravir, lopinavir, ritonavir TARGET	Raltegravir, lopinavir, ritonavir	Allina Health System	marketed	Antiretroviral combination therapy (integrase inhibitor + protease inhibitors)	HIV integrase, HIV protease
raltegravir and atazanavir and ritonavir	raltegravir and atazanavir and ritonavir	Giovanni Di Perri	marketed	Antiretroviral combination therapy (INSTI + PI + booster)	HIV integrase, HIV protease
Antiretroviral therapy	Antiretroviral therapy	ANRS, Emerging Infectious Diseases	marketed	Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors)	HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor
BIKTARVY Tablets (BIK)	BIKTARVY Tablets (BIK)	ViiV Healthcare	phase 3	Antiretroviral combination therapy (INSTI + NRTI + NRTI)	HIV reverse transcriptase, HIV integrase, HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (integrase inhibitor + protease inhibitors) class)

1. Allina Health System · 1 drug in this class